Clinical Trials on Herpesvirus 2, Human in Belgium

Total 554 results

Erasme University Hospital

Completed

Comparison Between Three Freezing Protocols to Preserve Human Embryos

Human Embryo Cryopreservation

Belgium
Universitaire Ziekenhuizen KU Leuven
Innovative Medicines Initiative; BELpREG

Recruiting

UmbrelLACT Study: Clinical Lactation Study on the Exposure to Medicines Via Human Milk (UmbrelLACT)

Breast Feeding | Human Milk

Belgium
Cliniques universitaires Saint-Luc- Université...

Unknown

Impact of Changes in Muscle Secretome in the Remission of Type 2 Diabetes Mellitus Induced by Bariatric Surgery (MYDIASECRET)

Diabete Type 2

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

Human Influenza

Belgium
University Hospital, Ghent
University Ghent

Completed

Reparation of Cartilage Injuries in the Human Knee by Implantation of Fresh Human Allogenic Chondrocytes

Cartilage Injuries in the Human Knee

Belgium
Cliniques universitaires Saint-Luc- Université...

Completed

Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes

Type 2 Diabetes Mellitus

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

Human Influenza

Belgium
University Ghent

Completed

Soft Tissue Responses Around Nanostructured Calcium-phosphate-coated Implant Abutments on Dental Implants: Histological, Genetic and Clinical Evaluation in Smokers and Non-smokers. (STRANDI)

Missing Several Teeth | Minimum of 2 Dental Implants Needed

Belgium
University of Liege
EGID, Lille

Unknown

Research Study for Rare Pathogenic Mutations Causing Type 2 Diabetes and Complications (PreciDiag)

Diabete Type 2

Belgium
University Ghent
BOF

Completed

Controlled Outcome Evaluations of a Daily Physical Activity Intervention for Individuals With Type 2 Diabetes

Type 2 Diabetes

Belgium
University Ghent

Completed

Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial

Diabetes Mellitus

Belgium
Erasme University Hospital

Terminated

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Type 2 Diabetes | Pancreas | Incretinomimetics

Belgium
University Hospital, Ghent

Completed

Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) (HPVXneutra001)

Infection With Human Papillomavirus

Belgium
Novartis Vaccines

Completed

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Influenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza Virus

Belgium
Universitair Ziekenhuis Brussel

Completed

HCG Versus Spontaneous LH in Intrauterine Insemination (IUI ) Cycles

Spontaneous Triggering of Ovulation vs. Administration of Human Chorionic Gonadotropin in Patients Undergoing IUI

Belgium
Universitaire Ziekenhuizen KU Leuven

Completed

Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus (AREBAG)

Type 2 Diabetes Mellitus

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects

Human Influenza

Belgium
Cliniques universitaires Saint-Luc- Université...

Completed

Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients

Psoriasis | Type 2 Diabetes

Belgium
University Ghent

Completed

Identifying the Effect and Working Mechanisms of MyPlan 2.0 in Adults With Type 2 Diabetes

Chronic Disease

Belgium
Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
University Hospital, Gasthuisberg

Completed

The Effect of a Gastric Bypass on Type 2 Diabetes in the Morbidly Obese Patient

Type 2 Diabetes | Morbid Obesity

Belgium
Université Catholique de Louvain
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Completed

Optimization of Darunavir Therapy and Dosage Recommendations

Human Immunodeficiency Virus I Infection

Belgium
Hasselt University
KU Leuven; Jessa Hospital; University Ghent

Recruiting

Prevention of Heart Failure in Type 2 Diabetes by Exercise Intervention (PROTECTION)

Type 2 Diabetes

Belgium
Hasselt University
Jessa Hospital

Completed

Effect of High-intensity Interval Training on Cardiac Function and Regulation of Glycemic Control in Diabetic Cardiomyopathy

Type2 Diabetes | Diabetic Cardiomyopathies

Belgium
Pfizer

Completed

Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants

Healthy Volunteers | Adult | Drug Interactions | Humans

Belgium
Universitaire Ziekenhuizen KU Leuven

Completed

Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

Hiv | Human Papilloma Virus | Organ Transplants

Belgium
GlaxoSmithKline
University Ghent

Completed

Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)

HIV Infections | Infection, Human Immunodeficiency Virus

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule

Hepatitis A

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule

Hepatitis A

Belgium
Ziekenhuis Oost-Limburg
Ziekenhuis Oost-Limburg

Recruiting

Characteristics of NAFLD Among Type 2 Diabetes Patients

Type2 Diabetes | Non-Alcoholic Fatty Liver Disease

Belgium
GlaxoSmithKline

Withdrawn

Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix®

Hepatitis A

Belgium
Crucell Holland BV

Completed

Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine

Hepatitis A

Belgium
Osivax
Center for vaccinology (CEVAC), University of Ghent

Completed

Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.

Influenza

Belgium
Osivax
Centre for vaccinology (CEVAC), University of Ghent

Completed

Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years

Influenza

Belgium
Osivax
Center for vaccinology (CEVAC), University of Ghent, Belgium

Completed

A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness.

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate

Influenza

Belgium
GlaxoSmithKline

Completed

Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population

Influenza

Belgium
Seqirus
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

Influenza

Belgium
Visterra, Inc.

Completed

Influenza Challenge Study of VIS410 in Healthy Volunteers

Influenza

Belgium
Crucell Holland BV

Completed

Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine

Influenza

Belgium
Novartis
Novartis Vaccines

Completed

A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age

Influenza

Belgium
Cyril Barbezange
Sciensano; Belgian Federal Public Service, Food Chain Safety and Environment; Agentschap Zorg en Gezondheid

Enrolling by invitation

Zoonotic Influenza Surveillance in Belgium (ZOOIS)

Influenza, Human

Belgium
Osivax
Aepodia

Completed

Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects

Influenza

Belgium
GlaxoSmithKline

Completed

Revaccination With Influenza Vaccine GSK1247446A

Influenza | Influenza, Human

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

Influenza

Belgium

3

Subscribe